Spotlighting innovators in obesity, Alzheimer's, and AI advancements.
FDA decision (PDUFA date) for brepocitinib in dermatomyositis is expected by September 30, 2026, with a potential commercial launch scheduled. A medium impact is estimated as this is a key regulatory milestone, and the event is scheduled.
The U.S. FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2026, for the Priority Review of the New Drug Application (NDA) for zilganersen. Low importance is estimated as the date itself typically has minimal immediate impact scheduled.
Natera is scheduled to release its Q2 2026 financial results after the market closes on August 6, 2026. This is a recurring, significant event, and its importance is estimated as High based on substantial market reactions to past earnings reports scheduled.
Q2 2026 earnings release and conference call on August 6, 2026, scheduled.
Viatris will report its second-quarter 2026 financial results on August 6, 2026, as announced on July 1, 2026. The event is scheduled.
Q2 2026 earnings release and conference call on August 5, 2026; low impact is estimated as the announcement is a routine scheduling event, scheduled.
Financial results for the first half of 2026, with importance estimated as Low based on typical market reaction to routine earnings dates, scheduled.
Amgen is scheduled to report its Q2 2026 financial results after the market closes on August 4, 2026; a high impact is estimated as quarterly earnings typically drive significant volatility, scheduled.
Q2 2026 earnings release and conference call scheduled. Earnings announcements typically trigger price movements of 5% or more, justifying a medium importance estimate scheduled.
Q2 2026 earnings release and conference call on 2026-08-04 scheduled.
AbbVie to announce second-quarter 2026 financial results before the market opens on 2026-07-31. High importance estimated due to potential for significant volatility following the report, scheduled.
Estimated Medium importance as earnings reports typically drive price movements of 5% or more; second quarter 2026 financial results and corporate update scheduled.
Alnylam is scheduled to report its financial results for the second quarter ending June 30, 2026, before the U.S. financial markets open, as announced on July 16, 2026. High importance is estimated as earnings reports for major biotech firms often result in ≥10% price impact. The event is scheduled.
Q2 2026 earnings release after market close. High importance estimated based on typical market impact of earnings reports, scheduled.
As earnings releases typically result in a 5-10% price impact, the Q2 2026 earnings release and conference call on July 30, 2026, is scheduled.
Regeneron is scheduled to report its second quarter 2026 financial and operating results on 2026-07-30; a medium impact is estimated as earnings reports typically drive significant volatility, scheduled.
Q2 2026 earnings release scheduled for 2026-07-30; analysts forecast revenue of approximately $12.6 billion. Medium importance as earnings typically drive 5-10% price movement, scheduled.
First quarter results for fiscal year 2026 are scheduled to be announced on July 30, 2026 scheduled. This routine announcement is estimated to have a >=1% price impact.
Ionis Pharmaceuticals is scheduled to host a webcast to discuss its second quarter 2026 financial results on July 29, 2026. Analysts forecast a loss per share of around $1.06 forecasted. Medium importance is estimated due to typical earnings volatility scheduled.
Q2 2026 Earnings Release scheduled. Earnings releases for major pharmaceutical firms typically result in price fluctuations of at least 5%.
Biogen is scheduled to report its Q2 2026 financial results on July 29, 2026, before the market opens; a price impact of at least 1% is estimated based on historical earnings volatility, scheduled.
Q2 2026 earnings results and portfolio growth update scheduled for release on July 28, 2026. Earnings releases typically result in a medium market impact (5-10%), scheduled.
IQVIA is scheduled to announce its second-quarter 2026 financial results before the market opens on July 28, 2026, with a conference call to follow. Low impact estimated as the actual results are not yet released, scheduled.
H1 and Q2 2026 earnings results scheduled to be released. A low impact is estimated as this is a routine financial disclosure scheduled.
RELX PLC is scheduled to release its H1 2026 earnings results on July 23, 2026. Analysts forecast EPS of approximately $0.89. A 5% price impact is estimated based on historical earnings volatility. This event is scheduled.
Second quarter 2026 financial results scheduled to be released before the market opens. This is a significant scheduled event that will provide an update on the company's performance. Estimated importance is Medium as quarterly earnings typically result in 5-10% price volatility scheduled.
Medpace is scheduled to report its second quarter 2026 financial results after the market close on July 22, 2026, with analysts forecasting EPS of approximately $3.98. High importance is estimated as earnings releases for this stock typically result in price movements exceeding 10%, and this event is forecasted.
Q2 2026 earnings release is scheduled for July 22, 2026, with analysts forecast of $2.57 EPS forecasted.
Novartis is scheduled to announce its financial results for the second quarter of 2026, scheduled.
Mike Sullivan's appointment as Chief Commercial Officer becomes effective on July 20, 2026, scheduled.
GSK announced on July 17, 2026, the discontinuation of the development of camlipixant for refractory chronic cough (RCC). This is expected to have a high impact (>10%) as it was a key asset from a $2 billion acquisition, scheduled.
The US FDA granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN). This converts the drug's 2024 accelerated approval to a full approval.
Presented positive secondary endpoint data from two Phase 3 studies for zasocitinib in plaque psoriasis at the AAD Innovation Academy on July 17, 2026. Positive clinical data for a key drug is estimated to have a >=5% price impact.
Abbott reported Q2 2026 adjusted EPS of $1.31, beating estimates of ~$1.28, and raised its full-year 2026 adjusted EPS guidance to $5.45-$5.60. This guidance raise is estimated to cause a 5-9% price impact expected.
Announced the first U.S. participant was dosed in the Phase 1 trial of mRNA-4200, an investigational cancer therapy for advanced solid tumors. Estimated Low importance as Phase 1 trial starts typically result in price movements of 1-5%.
Positive results from the Phase 3 KEYNOTE-C93 trial for Keytruda in dMMR endometrial cancer patients are expected. High impact (>10%) estimated due to significant market expansion expected.
Alnylam announced progress in its neuroscience portfolio at the AAIC 2026 conference, including the initiation of a Phase 2 study of mivelsiran for Alzheimer's disease and the completion of enrollment for a separate Phase 2 study in cerebral amyloid angiopathy (CAA).
Johnson & Johnson reported Q2 2026 revenue of $25.3 billion (+6.6% YoY) and adjusted EPS of $2.90, beating analyst estimates. The company raised its full-year 2026 guidance for both sales and earnings.
The ex-dividend date for a quarterly cash dividend of $0.63 per share is July 15, 2026. Routine dividends typically have a price impact of 1-4% scheduled.
The European Commission (EC) approved the once-daily oral version of Wegovy and a higher dose injection pen on July 15, 2026, resulting in a 3% stock price increase.
Announced an exclusive license agreement with Dizal Pharmaceutical to acquire worldwide rights to Zegfrovy, an oral lung cancer therapy. The deal includes a $600 million upfront payment and up to $900 million in milestones.
Biogen presented detailed Phase 2 data for its Alzheimer's drug diranersen at the AAIC conference on July 14, 2026. The data showed mixed results, with the study technically failing its primary endpoint due to an inverse dose response, causing the stock to drop over 8%.
A Munich court ruled on July 14, 2026, that Illumina infringed on a patent from Element Biosciences related to DNA sequencing technology.
On July 14, 2026, partner Biogen presented positive Phase 2 data for diranersen in early Alzheimer's disease, showing meaningful clinical efficacy. Medium importance is estimated based on the clinical significance of Alzheimer's treatments.
The U.S. FDA approved LEQEMBI IQLIK, a subcutaneous (at-home) injection, as an initiation dose for early Alzheimer's disease on July 13, 2026. This provides a more convenient alternative to IV infusions, and the stock rose approximately 5% on the news.
The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for mezigdomide on July 13, 2026, for patients with relapsed or refractory multiple myeloma. The target action date is May 13, 2027.
Announced positive interim results on July 13, 2026, from the registrational phase II AZUR-1 trial for Jemperli (dostarlimab). Positive clinical data is expected to have a medium market impact (5-10%), scheduled.